Acticor Biotech, a company specializing in the development of glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announced the results of its collaboration with Brainomix Limited for artificial intelligence (AI) analysis of brain imaging results from stroke patients in a Phase 1b/2a ACTIMIS study.

"Preliminary results appear to show that glenzocimab not only reduces the occurrence of intracranial hemorrhages, but also their volume, compared with placebo", points out Yannick Pletan, Chief Operating Officer and Chief Medical Officer of Acticor Biotech.

' This analysis, carried out in our laboratories, enabled us to precisely identify the mode of action and demonstrate the efficacy of glenzocimab. It also demonstrated that glenzocimab reduces the size of brain lesions after thrombolysis in stroke, and identified subgroups of patients who appear to derive greater clinical benefit', adds George Harston, Brainomix Medical Director and Consultant Stroke Physician.

Consequently, the biopharmaceutical company has announced that the results of the ACTIMIS study will be submitted for publication at forthcoming international congresses.


Copyright (c) 2023 CercleFinance.com. All rights reserved.